Evaluate the safety, tolerance and efficacy of hydroxychloroquine sulfate tablets the prevention and treatment of oral mucositis and dysgeusia in patients undergoing radiotherapy
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
158
the trial group use the hydroxychloroquine sulfate tablets (200mg/time, bid)
the control group use the Placebo
Department of Radiation Oncology
Chengdu, Sichuan, China
RECRUITINGthe WHO grade of RIOM
use the WHO Oral Toxicity Scale to evaluate the WHO grade of RIOM. WHO O grade: no representation of RIOM; WHO 1 grade: soreness and erythema; WHO 2 grade: erythema, ulcers and ability to eat solids; WHO 3 grade: ulcers, requiring liquid diet; WHO 4 grade: alimentation not possible. The higher scores mean a worse outcome.
Time frame: From the start of radiotherapy to 8 weeks after completion of radiotherapy
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.